based on remarkable activity in refractory lymphomas , a combination of etoposide , cisplatin ( both administered by 4-day continuous infusions ) , cytarabine ( ara-c ) , and dexamethasone ( edap ) was evaluated in 20 patients with advanced myeloma refractory to standard melphalan and prednisone ( mp ) and/or vincristine , adriamycin ( doxorubicin ; adria laboratories , columbus , oh ) , and dexamethasone ( vad ) and even to high doses of melphalan ( hdm ) ( seven patients ) .
C0024299
lymphomas
C0010711
cytarabine